

**Public**

## Environmental and Social Data Sheet

### Overview

Project Name:	Pharma and medical devices programme
Project Number:	20210113
Country:	Germany
Project Description:	The project relates to the promoter's expenditures in Research, Development and Innovation in its portfolio of biosimilars, generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.
EIA required:	no
Project included in Carbon Footprint Exercise <sup>1</sup> :	no

### Environmental and Social Assessment

#### Environmental Assessment

The project's RDI activities are a central part of the promoter's operations and will be embedded in the existing organisational and management structure.

R&D activities included in the project will not materially change current R&D practice and will be carried out within existing and already authorised facilities. This type of activities is not specifically listed in Directive 2011/92/EU, as amended; therefore an Environmental Impact Assessment (EIA) is not required.

The promoter's practices are in compliance with the relevant national and EU regulations (directives 2001/83/EC, 2005/28/EC, 2001/20/EC) and applicable good practice quality guidelines and regulations.

#### Social Assessment, where applicable

The project will generate positions accessible to highly qualified RDI workers EU, which would provide increased access to social and economic benefits. The promoter is an equal opportunity employer, committed to gender equality, actively supporting women in science.

#### Other Environmental and Social Aspects

Through the RDI activities and investments, the promoter expects to increase its current level of highly skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

---

<sup>1</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20,000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.

Luxembourg, 12 November 2021

## **Conclusions and Recommendations**

The project concerns investments in research and development in human health products that will be carried out in existing facilities without changing their already authorised scope. The activities are not covered under the EIA Directive 2014/52/EU amending Directive 2011/92/EU. The promoter complies with all relevant regulations and recommendations related to its business. The research activities undertaken in the project are aimed at delivering novel and improved medical devices and medicinal products with a positive impact on healthcare. Therefore, the project, if successful, is expected to bring positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects